Moreover, MΦ reprogramming overcomes AML blast resistance to two standard anti-AML therapies, the FMS-like tyrosine kinase 3 (FLT3) inhibitor midostaurin and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. This evidence concerns the gene BCL2 and acute myeloid leukemia.